ViVitro Labs Acquires ProtomedLabs to Expand Global Footprint and Enhance Cardiovascular Testing Capabilities

On September 18, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that ViVitro Labs announced the acquisition of ProtomedLabs SASU, a medical device testing laboratory based in France. The specific transaction amount was not disclosed.

Upon completion of the transaction, the two companies will merge their operations and form a single entity operating under the name ViVitro Labs. This acquisition expands ViVitro’s presence across Europe and doubles the company’s contract testing and customization capabilities. Karim Mouneimne, General Manager of ProtomedLabs, will serve as President of the merged company.

Led by CEO Scott Phillips, ViVitro Labs provides cardiovascular testing equipment along with related laboratory testing and consulting services. For over 30 years, hundreds of organizations in more than 30 countries have relied on ViVitro’s expertise, accuracy, and quality in the testing of heart valves, LVADs, TAHs, stents, and grafts. ViVitro Laboratory Services holds ISO 5840 and ISO/IEC 17025 certifications. The ViVitro Pulse Duplicator system is the most widely used in vitro cardiovascular hemodynamic testing system in the world.

ProtomedLabs, led by President and Chief Executive Officer Frederic Mouret, is an ISO 17025-certified medical device testing laboratory that provides device testing solutions for companies developing implantable and interventional cardiovascular devices. Headquartered in Marseille, France, ProtomedLabs is wholly owned by Protomed SA, based in Strasbourg, France. Protomed SA is an ISO 13485-certified contract research and development organization specializing in the design and development of medical devices.

Scott Phillips, CEO of ViVitro Labs, stated, “This acquisition and merger fulfill our commitment to customers to expand ViVitro’s resources, products, and services, while also meeting the evolving cardiovascular testing system needs of cutting-edge researchers and organizations.”

Frederic Mouret, President and CEO of Protomed SA and owner of ProtomedLabs, stated, “Since 2015, ProtomedLabs has served as the sales distributor for ViVitro in Europe, Israel, and Africa. We are delighted to elevate this successful partnership to a new level.”

Karim Mouneimne, President of the new company, stated, “It has long been our tradition to help companies address their testing challenges by leveraging ViVitro’s equipment and customized testing strategies. The expanded production capacity of the new entity will enable us to actively enrich and refine our product portfolio, offering cardiovascular industry clients a more diverse range of customized services.”

(Compiled by Tian Shuhang)